HighTide

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

Retrieved on: 
Thursday, January 5, 2023
T2DM, Food, Venture round, PSC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Primary sclerosing cholangitis, NASH, Trial of the century, Series, HighTide, Patient, Fatty liver disease, FDA, Pharmaceutical industry, MD

Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.

Key Points: 
  • Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.
  • "After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round.
  • "The Series C/C+ financing is a significant milestone for HighTide.
  • It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations."

American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

Retrieved on: 
Wednesday, November 16, 2022
AST, ALP, Type 2 diabetes, Malignancy, Serum, Liver transplantation, HighTide, PSC, Risk, Liver disease, GGT, Therapy, Hypertriglyceridemia, Primary sclerosing cholangitis, Patient, IBD, Liver failure, Orphan drug, Fast Track, NASH, Inflammation, Disease, T2DM, News, Cirrhosis, ALT, Ulcerative colitis, Fibrosis, The American Journal of Gastroenterology, Inflammatory bowel disease, Crohn's disease, American Journal, Safety, Fatty liver disease, Pharmaceutical industry, Medical imaging, MD

This study met the primary endpoint and multiple key secondary endpoints, demonstrating the safety and efficacy of HTD1801 in treating PSC.

Key Points: 
  • This study met the primary endpoint and multiple key secondary endpoints, demonstrating the safety and efficacy of HTD1801 in treating PSC.
  • Data show that compared to placebo, both low and high doses of HTD1801 treatment could significantly reduce serum ALP levels.
  • In addition, HTD1801 significantly reduced alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT), further supporting the beneficial effects of HTD1801 in treating PSC.
  • The improvements in ALP we observed in this study, along with the excellent safety profile of HTD1801, are promising.

HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022

Retrieved on: 
Tuesday, October 25, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Dysbiosis, Risk, Therapy, Non-alcoholic fatty liver disease, T2DM, American Association for the Study of Liver Diseases, Population, Gut microbiota, Cholestasis, Alkaline phosphatase, Lists of diseases, Liver injury, Primary sclerosing cholangitis, HIV disease progression rates, Fatty liver disease, Orphan drug, NASH, Liver, AASLD, HighTide, American Association, Association, 2021 Essex County Council election, Fast Track, ALP, PSC, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Dietary supplement, Patient

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).
  • Emerging evidence supports the bidirectional relationship between intestinal microbiota and liver health.
  • Dysbiosis has been associated with the pathogensis and progression of multiple metabolic diseases and chronic inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
  • Presentations at the Liver Meeting 2022 include:
    We are very pleased to share these data, said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide.

HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development

Retrieved on: 
Thursday, October 20, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, San Diego State University, Therapy, T2DM, Business administration, Master of Business Administration, Primary sclerosing cholangitis, Business, Fatty liver disease, Orphan drug, Senior, Partnership, NASH, Ionis Pharmaceuticals, HighTide, Novartis, Apricus Biosciences, CEO, Business development, Fast Track, Conatus, Head, PSC, Solution, Greater China, Program, Pharmaceutical industry, Management, Microbiology

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
  • Mr. Ripley has 25 years of experience in pharmaceutical business development.
  • Prior to Alpha Biopharma, Mr. Ripley served in several senior business development roles.
  • Prior to Conatus, Mr. Ripley was Senior Director, Business Development at Apricus Biosciences and Director, Business Development at Ionis Pharmaceuticals.

HighTide Therapeutics Announces Early Completion of Enrollment in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

Retrieved on: 
Tuesday, August 30, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Cardiovascular disease, Mortality, Diabetes, Chinese, COVID-19, HIV disease progression rates, Glycated hemoglobin, CEO, Non-alcoholic fatty liver disease, Safety, Dyslipidemia, Obesity, Liver, Therapy, Roy Taylor (scientist), Institute of Liver and Biliary Sciences, Time, A1C, Disease, Death, Decision-making, Risk, HighTide, Fatty liver disease, Cirrhosis, Hepatocellular carcinoma, Department, Prognosis, Glycemia, Kidney disease, Goal, Peking University, Type 2 diabetes, Hospital, Prevalence, Hypertension, Comorbidity, NASH, Biomarker, Adult, T2DM, End organ damage, Patient, Pharmaceutical industry, NAFLD, Hyperuricemia, Endocrinology

HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
  • The study enrolled 113 subjects, and the endpoints include the change in hemoglobin A1c (HbA1c) after 12 weeks of treatment as well as changes in biomarkers of NAFLD.
  • Previous Phase 2 study in adults with comorbid nonalcoholic steatohepatitis (NASH) and T2DM completed in the United States demonstrated overall clinical benefits across liver, lipid, glycemia, weight, metabolic, and cardiovascular health.
  • The multi-functional HTD1801 developed by HighTide aims to provide patients with broad clinical benefit across glycemia, liver, and cardiovascular health.

High Tide President and CEO, Raj Grover, Named Cannabis Person of the Year at O'Cannabiz Industry Awards Gala

Retrieved on: 
Thursday, June 2, 2022
Leadership, Goal, TSX Venture 50, Company, TSX Venture Exchange, Corporation, CEO, AZ Business Magazine, Forward-looking statement, News, Government, SEDAR, BC Liquor Distribution Branch, Senior, HighTide, Multimedia, Humble Bundle, Alcohol and Gaming Commission of Ontario, CBD, Work, Person, Saskatchewan Liquor and Gaming Authority, TSX, EDGAR, AB, Industry, High Tide, FSE, Best, Green Grass and High Tides, Tide, Terminology, Drug, Retail, Security (finance)

"I am truly humbled and honoured to be named Cannabis Person of the Year but this recognition is one I can't accept alone.

Key Points: 
  • "I am truly humbled and honoured to be named Cannabis Person of the Year but this recognition is one I can't accept alone.
  • High Tide's success is built not only upon our diversified cannabis ecosystem, but also the diversity of our leadership team.
  • Social equity and corporate social responsibility are core to what we are trying to build at High Tide.
  • I want to reiterate my commitment to being a champion for these causes within the broader cannabis sector," added Mr. Grover.

HighTide Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Adult, A1C, CEO, Fatty liver disease, Roy Taylor (scientist), Association, Patient, Glycated hemoglobin, Hypertriglyceridemia, Incidence, Therapy, Cirrhosis, Cardiovascular disease, HighTide, Liver, Prevalence, Primary sclerosing cholangitis, Primary biliary cholangitis, Insulin resistance, Hepatocellular carcinoma, Trial of the century, NASH, Risk, NAFLD, Population, Safety, Pharmaceutical industry, T2DM

HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
  • T2DM and NAFLD remain the most common chronic diseases worldwide with rapidly increasing prevalence and incidence.
  • Given the strong association and overlapping pathophysiology, there is a sizable population of patients with comorbid T2DM and NAFLD.
  • The complex pathophysiology of T2DM and NAFLD requires the engagement of multiple mechanistic pathways to optimize pharmacological intervention.

HighTide Therapeutics Appoints Myleen Leoncavallo as SVP Regulatory Affairs and Quality Assurance

Retrieved on: 
Thursday, March 31, 2022
Biotechnology, General Health, Pharmaceutical, Health, Drug development, BioMarin Pharmaceutical, Therapy, University, Primary biliary cholangitis, Degenerative disease, Master of Science, Institute of Liver and Biliary Sciences, Regulatory affairs, Quality assurance, Cholestasis, Primary sclerosing cholangitis, Pregnancy, Biliary atresia, Medicinal chemistry, University of California, San Diego, HighTide, Cholestatic pruritus, Senior, Cell biology, T2DM, Alagille syndrome, Clinical trial, Hypertriglyceridemia, Patient, Pharmaceutical industry, Biochemistry, Science, Spiroplasma mirum

HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.
  • Mrs. Leoncavallo will report to Dr. Leigh MacConell, Chief Development Officer of HighTide.
  • We are very pleased to welcome Myleen to HighTide, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.
  • Prior to Mirum, Mrs. Leoncavallo served in several senior regulatory affairs roles, including positions at Ultragenyx Pharmaceuticals and BioMarin Pharmaceuticals, biopharmaceutical companies focused on rare diseases.

HighTide Therapeutics Announces End-of-Phase 2 Meeting with FDA and Agreement to Proceed to Phase 3 for HTD1801 for the Treatment of PSC

Retrieved on: 
Tuesday, February 22, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Roy Taylor (scientist), Lists of diseases, Primary biliary cholangitis, Serum, ALP, Alkaline phosphatase, Therapy, Review, T2DM, Food, Adult, Degenerative disease, Comment, Fatty liver disease, FDA, Patient, NAFLD, NASH, HighTide, PSC, Primary sclerosing cholangitis, Food and Drug Administration, Hypertriglyceridemia, Pharmaceutical industry

As previously announced, the company completed a Phase 2 study of HTD1801 in patients with PSC.

Key Points: 
  • As previously announced, the company completed a Phase 2 study of HTD1801 in patients with PSC.
  • This dose-ranging, double-blind, placebo-controlled Phase 2 clinical trial evaluated the treatment effects of HTD1801 in 55 adult patients with PSC conducted at over 20 clinical sites in the U.S. and Canada.
  • Serum levels of gamma-glutamyl transferase, alanine aminotransferase, and aspartate aminotransferase also were reduced with both doses of HTD1801 compared with placebo.
  • We would like to acknowledge the helpful guidance that FDA has provided, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.

HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology

Retrieved on: 
Thursday, January 6, 2022
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, NASH, Therapy, University, Fatty liver disease, Chronic liver disease, Roy Taylor (scientist), Lists of diseases, Patient, Primary biliary cholangitis, IND, T2DM, Chen Jin, Pharmacology, Buffalo, NAFLD, PSC, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Degenerative disease, SVP, Institute of Liver and Biliary Sciences, Drug, Clinical pharmacology, Amgen, State, Primary sclerosing cholangitis, HighTide, State university system, PBC, NDA, Pharmaceutical industry, Novartis

HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.

Key Points: 
  • HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.
  • Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development.
  • Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio, renal, metabolic, and liver diseases.
  • We are very pleased to welcome Jin to the HighTide team, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.